Q3 2024 Iovance Biotherapeutics Inc Earnings Call Transcript
Key Points
- Iovance Biotherapeutics Inc (IOVA) reported third-quarter total product revenue of $58.6 million, surpassing their guidance of $53 million to $55 million.
- Amtagvi's adoption and demand are strong, with 126 patients infused since its launch, indicating robust market acceptance.
- The company has favorable medical coverage policies, with approximately 75% of Amtagvi patients covered by private payers.
- Iovance Biotherapeutics Inc (IOVA) is expanding its network of authorized treatment centers (ATCs), aiming to reach 70 ATCs by year-end.
- The company is on track to achieve its full-year 2024 revenue guidance of $160 million to $165 million and anticipates significant revenue growth in 2025 and beyond.
- The company reported a net loss of $83.5 million for the third quarter of 2024, although this is an improvement from the previous year.
- There are concerns about potential impacts on infusion schedules due to upcoming holidays, which could affect revenue projections.
- The cost of sales remains high, with $39.8 million reported for the third quarter, impacting gross margins.
- Research and development expenses, although decreased, remain substantial at $68.2 million for the third quarter.
- The company is still working on optimizing manufacturing processes to improve turnaround times and reduce costs.
Thank you for standby. My name is Mandeep, and I'll be your operator today. I'd like to welcome everyone to the Iovance Third Quarter 2024 Financial results call.
I would now like turn the call over to Sara.
Thank you, operator. Good afternoon, and thank you for joining this conference call and webcast to discuss our third quarter and year-to-date 2024 financial results as well as recent corporate and development program updates.
Dr. Fred Vogt, our Interim Chief Executive Officer and President, will provide an introduction and summarize the latest progress with our US commercial launch of Amtagvi including revenue and revenue guidance, patient demand and market access, an update on our global regulatory submissions at a high-level summary of our key pipeline. Dr. Brian Gastman, our Executive Vice President, Medical Affairs, will highlight adoption and demand at authorized treatment centers or ATC as well as our community outreach initiatives to drive
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
